Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
16 hedge funds and large institutions have $13.4M invested in Calliditas Therapeutics AB American Depositary Shares in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
4,800% more call options, than puts
Call options by funds: $637K | Put options by funds: $13K
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
14% less capital invested
Capital invested by funds: $15.6M → $13.4M (-$2.23M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$784K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
+$204K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$54.2K |
| 4 |
Jane Street
New York
|
+$15.4K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$6.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$55.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$6.57K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$5.92K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$2K |
CALT Hedge Fund Activity: Q3 2022 in Review
16 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q3 2022, worth a combined $13.4M — down 14% from $15.6M a quarter earlier.
Fund positioning in CALT was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was HBK Sorce Advisory, opening a new position worth an estimated $784K. The largest seller was Morgan Stanley, cutting an estimated $55.1K.
- 16 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $13.4M of Calliditas Therapeutics AB American Depositary Shares stock for Q3 2022, down 14% quarter-over-quarter.
- 2 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q3 2022 and 2 closed out, a net change of 0 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q3 2022 was HBK Sorce Advisory, an estimated $784K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q3 2022 was Morgan Stanley, an estimated $55.1K sold.
Based on aggregated 13F filings for Q3 2022.